NPCE - Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point Competitive Position | Benzinga
Cantor Fitzgerald initiated coverage on NeuroPace Inc (NASDAQ: NPCE), a commercial-stage medical device company focused on drug-resistant epilepsy treatment through the company's responsive neurostimulation device (RNS).
The analyst Ross Osborn initiates with an Overweight rating and a price target of $11.
He notes the company addresses a currently estimated ~$2 billion market opportunity based on the 1.2 million people living with drug-resistant epilepsy ...